Edwards Lifesciences (EW) Free Cash Flow (2009 - 2026)

Edwards Lifesciences' Free Cash Flow history runs 18 years deep, the most recent figure standing at -$21.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 109.4% year-over-year to -$21.1 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 72.09% YoY), while the FY2025 annual figure was $1.3 billion, up 360.5% from the prior year.
• Free Cash Flow was -$21.1 million for Q1 2026 at Edwards Lifesciences, down from $353.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $516.2 million in Q3 2025 to a low of -$177.3 million in Q4 2024.
• Historically, Free Cash Flow has averaged $189.4 million across 5 years, with a median of $240.9 million in 2025.
• Biggest YoY gain for Free Cash Flow was 2100.7% in 2024; the steepest drop was 467.08% in 2024.
• A 5-year view of Free Cash Flow shows it stood at $213.9 million in 2022, then sank by 77.42% to $48.3 million in 2023, then tumbled by 467.08% to -$177.3 million in 2024, then jumped by 299.38% to $353.5 million in 2025, then sank by 105.97% to -$21.1 million in 2026.
• The last three Free Cash Flow figures came in at -$21.1 million (Q1 2026), $353.5 million (Q4 2025), and $516.2 million (Q3 2025), per Business Quant data.